Andrew Huberman's Peptides Masterclass with Dr. Bakri (June 2026): Compound-by-Compound

The episode that reset the peptide conversation

On June 1, 2026, Andrew Huberman released a nearly three-hour episode of Huberman Lab focused entirely on peptide therapeutics. His guest, Dr. Abud Bakri, is a board-certified internal medicine physician who runs a peptide-focused clinical practice. The episode reached millions of listeners in its first month and quickly became one of the most-cited resources in the peptide space.

The timing mattered. The episode landed roughly eight weeks before the FDA's Pharmacy Compounding Advisory Committee (PCAC) hearing held July 23-24, 2026, which reviewed seven peptides for 503A compounding eligibility, including several of the compounds Huberman and Bakri discussed, and recommended six of them. See our FDA PCAC July 2026 article for the regulatory framework.

What follows is a compound-by-compound walkthrough of the peptides discussed in the episode, with links to our detailed peptide pages so you can dig into the underlying evidence.

BPC-157

What Huberman and Bakri covered: The gastric origin of BPC-157 (isolated from a fragment of a larger protective peptide found in gastric juice), the extensive rodent injury-model literature, the gap between animal and human evidence, and the neurological effects some users report anecdotally.

Site coverage: BPC-157 has one of the largest evidence bases in the research peptide space for tendon and ligament injury applications, though completed human RCTs are absent. It is under review at the FDA PCAC July 23-24, 2026 hearing. See our BPC-157 peptide page for the detailed mechanism, evidence, and community protocol frameworks. For BPC-157's role in tendon injury specifically, see our BPC-157 tendon injury dosing guide. For the BPC-157 + TB-500 combination Huberman and Bakri discussed, see the Recovery Classic stack page.

What's changed since the episode: Nothing substantially in the six weeks since air date, but the July PCAC review is now imminent. Users currently accessing BPC-157 through compounding pharmacies should be tracking the outcome, see our PCAC article.

GHK-Cu (Copper Tripeptide-1)

What Huberman and Bakri covered: GHK-Cu's role in wound healing, the anti-inflammatory pathway involvement, the collagen synthesis mechanism, and the emerging research on copper peptide complexes broadly. Bakri emphasized the difference between topical (well-evidenced) and systemic (less-evidenced) use.

Site coverage: GHK-Cu has decades of cosmetic-grade clinical evidence and one of the strongest evidence bases in the peptide space. See our GHK-Cu peptide page. For the topical vs systemic decision framework, see our GHK-Cu vs AHK-Cu comparison. For applications in specific contexts, see our Best peptides for skin anti-aging 2026 ranking, our Best peptides for hair loss 2026 ranking, and our Glow Stack page.

The community-standard topical protocol combines GHK-Cu 10% with AHK-Cu 5% in scalp and skin serums. The community-driven systemic protocol pairs subcutaneous GHK-Cu with BPC-157 and oral collagen peptides for broader anti-aging support.

Epitalon (Epithalon)

What Huberman and Bakri covered: Epitalon as a synthetic tetrapeptide based on the natural pineal peptide epithalamine, its Khavinson-tradition telomere-length and pineal-function evidence, and the broader Khavinson short peptide framework. Bakri discussed the tradition-specific limitations, most of the Epitalon evidence base originates from Vladimir Khavinson's research lineage in St. Petersburg, with limited independent Western replication.

Site coverage: See our Epitalon peptide page for the detailed mechanism and evidence framework, and our Khavinson short peptides page for the broader lineage context. Epitalon is one of the seven peptides under FDA PCAC review July 23-24, 2026, if the hearing outcome expands compounding-pharmacy access, this could be a significant access shift for users interested in circadian rhythm and longevity applications.

For related Khavinson-tradition compounds discussed in the community: Pinealon (which Huberman has separately discussed for REM sleep), Vilon, Thymalin, and Thymogen.

GLP-1 medications

What Huberman and Bakri covered: The current state of GLP-1 therapy for obesity and diabetes, the tirzepatide-vs-semaglutide comparison, the emerging retatrutide data, and the broader landscape of what's coming through Phase 3 trials.

Site coverage: For the foundational compound coverage: Semaglutide, Tirzepatide, and Retatrutide. For direct comparisons: Ozempic vs Mounjaro, Wegovy vs Zepbound, and Rybelsus vs Ozempic. For the pipeline landscape: our Next-generation GLP-1 pipeline 2026-2028.

Since the episode: Lilly announced TRIUMPH-1 topline results on May 21, 2026 with retatrutide showing 28.3% average weight loss at 80 weeks on the 12 mg dose (30.3% at 104 weeks among participants with baseline BMI 35 or above who continued in the extension), the deepest weight-loss result reported for any pharmacological obesity intervention. TRIUMPH-4 (obesity + knee osteoarthritis) reported 28.7% at 68 weeks in December 2025. These readouts confirm the Phase 2 signal at Phase 3 scale.

For the GLP-1 hub landing: GLP-1 medications hub. For the specific concerns users raise about GLP-1s: GLP-1 hair loss, GLP-1 muscle loss, GLP-1 side effects week by week.

Peptides Huberman has separately discussed

Pinealon

Not covered in the June 1 Bakri episode specifically, but Huberman disclosed use of Pinealon for REM sleep optimization earlier in 2026, which drove substantial community interest in the compound. Pinealon is an Ala-Glu-Asp tripeptide from the Khavinson family. See our Pinealon peptide page and our Best peptides for sleep 2026 ranking for the full framework.

Klotho

Huberman has separately discussed klotho biology in longevity contexts. See our Klotho peptide page.

MOTS-c and Humanin

Mitochondrial-derived peptides that fit the mitochondrial biology framework Huberman has discussed. See our MOTS-c page, Humanin page, and our Mitochondrial Triad Stack.

What the episode didn't fully cover

Three-hour episodes still have to make selections. The episode focused on the most-discussed peptides and their broad mechanism/evidence framings rather than covering the full research peptide space. Users looking for coverage of compounds not deeply addressed in the episode:

• KPV, anti-inflammatory tripeptide whose human evidence is limited (the most-cited clinical work involved a KPV-based candidate, and FDA judged the human record insufficient). PCAC recommended it 8-6 on July 23, 2026. See our KPV peptide page.
• TB-500 (Thymosin Beta-4 fragment), actin-binding peptide for tissue repair. See our TB-500 peptide page and BPC-157 vs TB-500 comparison.
• Melanocortin peptides (Melanotan II, PT-141), tanning and sexual function applications with distinct safety considerations. See the Melanotan II page and PT-141 page.
• Growth hormone secretagogues (Ipamorelin, CJC-1295, Tesamorelin), GH-axis stimulation for body composition. See Ipamorelin, CJC-1295, Tesamorelin, and our three-way GH-axis comparison.
• Selank and Semax, Russian nootropics with anxiolytic and cognitive effects respectively. See Selank and Semax. Semax is under PCAC review July 23-24, 2026.

The regulatory backdrop

The June 1 episode timing was consequential because it substantially amplified peptide interest right before the FDA's PCAC hearing on July 23-24, 2026. That hearing reviewed seven peptides for compounding-pharmacy eligibility: BPC-157, TB-500, KPV, MOTS-c on July 23; DSIP (Emideltide), Semax, and Epitalon on July 24.

PCAC recommendations are non-binding, and formal FDA rulemaking would still be required after the hearing, a process that under standard timelines can take more than a year. But the hearing outcome will shape the regulatory environment for compounded peptide access for years.

For the framework: our FDA PCAC July 2026 article. For broader regulatory environment context including the March 2026 DOJ enforcement actions: our State of the Peptide Market 2026.

Sourcing and safety framework

Huberman and Bakri emphasized that peptide sourcing quality varies enormously. For evaluation frameworks:

• How to read a peptide Certificate of Analysis (COA)
• How to evaluate peptide vendors
• Peptide storage guide
• Are peptides safe?
• High-caution peptides
• Peptide side effects guide
• Peptide drug interactions

What the episode changes

Mainstream podcast coverage of peptides at Huberman's audience scale has three predictable effects: substantially increased search volume for the compounds discussed, downstream vendor demand pressure that affects supply and pricing, and increased attention from regulators, media, and healthcare institutions. All three effects are visible in the current environment.

For users approaching peptides for the first time after hearing the episode: the compounds have distinct evidence bases, safety profiles, and community protocols. Working with a knowledgeable prescriber matters more than compound-by-compound optimization from a single podcast episode. Our peptide pages are structured to give you the specific compound-level evidence framework you need to make appropriate decisions.